A study, led by the Clinical Hematology Service of the Catalan Institute of Oncology of Girona (ICO) - Biomedical Research Institute of Girona dr. Josep Trueta (IDIBGI) -Josep Carreras Research Instit...
Read moreThe U.S. Food and Drug Administration (FDA) approves cell therapy for patients with blood cancers to reduce the risk of infection after stem cell transplantation.
Read moreHan desarrollado una calculadora que identifica los pacientes con mieloma múltiple y amiloidosis sistémica primaria que presentan mejor pronóstico al tener un perfil más benigno.
Read moreThe research has focused on the study, using methods based on proteomics and immunohistochemistry techniques, to explore the extent of inflammatory and immune responses in subjects with CADASIL
Read moreUn estudio demuestra que las variantes estructurales pueden ser responsables de una proporción significativa de defectos genéticos en el gen F11 asociados con la deficiencia de FXI.
Read moreDiseases such as stroke, heart attack or pulmonary embolism are mostly the consequence of a thrombosis; that is, a blood clot, which normally forms due to coagulation problems.
Read moreVarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it has successfully raised an additional €30 million in a Series B2...
Read moreLos resultados de esta investigación ponen en evidencia la necesidad de seguir buscando opciones terapéuticas que ayuden a conseguir, tras el infarto, una completa llegada de flujo sanguíneo al mio...
Read moreHan financiado el desarrollo de una terapia celular pionera que utiliza la inmunoterapia y la tecnología RNA para tratar a pacientes con cánceres hematológicos que no responden a los tratamientos c...
Read moreInvestigadores de la UPM y el CIBER-BBN participan el proyecto ALMA, que desarrollará modelos de biomarcadores para patologías como la leucemia mieloide aguda o el síndrome mielodisplásico
Read moreBoth centers initiate three pioneering biomedical projects combining artificial intelligence, cutting-edge technology Genetics and advanced therapies
Read moreIt is the first treatment in the last 30 years that represents a relative improvement of 38% in the overall survival of patients compared to standard treatment. The results of Phase III study ZUMA-7 ...
Read more